🇺🇸 pegylated interferon-alfa in United States

324 US adverse-event reports

Safety signals — FAERS

Adverse reaction reports describe suspected side effects. A report does not mean the drug caused the event — co-medications, underlying disease and coincidence all contribute.

• Window: 22 April 2025 – 22 April 2026
• Total reports: 324

Most-reported reactions

1. Anaemia — 56 reports (17.28%)
2. Fatigue — 47 reports (14.51%)
3. Anti-Neutrophil Cytoplasmic Antibody Positive Vasculitis — 45 reports (13.89%)
4. Nausea — 32 reports (9.88%)
5. Rash — 30 reports (9.26%)
6. Vomiting — 26 reports (8.02%)
7. Diarrhoea — 23 reports (7.1%)
8. Drug Ineffective — 22 reports (6.79%)
9. Hepatitis C — 22 reports (6.79%)
10. Dyspnoea — 21 reports (6.48%)

Source database →

Frequently asked questions

Is pegylated interferon-alfa approved in United States?

pegylated interferon-alfa does not currently have US marketing authorisation in our dataset.

Who is the marketing authorisation holder for pegylated interferon-alfa in United States?

Third Affiliated Hospital, Sun Yat-Sen University is the originator. The local marketing authorisation holder may differ — check the official source linked above.